Nivolumab Plus Ipilimumab Improves Overall Survival Over Standard of Care Therapy in Advanced Non-Clear Cell Renal Cancer
Final Results From the Phase 2 SUNNIFORECAST Trial
Final Results From the Phase 2 SUNNIFORECAST Trial
Lothar Bergmann, MD, J.W. Goethe University Frankfurt, Germany, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of nivolumab plus ipilimumab vs standard of care (SOC) therapy in treatment-naive patients with advanced non-clear cell renal cancers. Study findings showed that nivolumab plus ipilimumab demonstrated significantly higher 12-month and median overall survival than SOC therapy in this patients population.
Dr Bergmann presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Source:
Bergmann L, Ahrens M, Albiges L, et al. Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer-results of the SUNNIFORECAST trial. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract LBA75
